These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8622491)

  • 1. Treatment of benign prostatic hyperplasia. The Scandinavian BPH Study Group.
    Andersen JT
    Lancet; 1996 May; 347(9010):1270. PubMed ID: 8622491
    [No Abstract]   [Full Text] [Related]  

  • 2. [Benign prostatic hyperplasia. Finasteride controls progression of BPH].
    MMW Fortschr Med; 2000 Jun; 142(25):62-3. PubMed ID: 10920676
    [No Abstract]   [Full Text] [Related]  

  • 3. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P; Andersen JT; Wolf H
    Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ; Beisland HO; Andersen JT; Wolf H; Ekman P; Johansson JE; Kontturi M; Lehtonen T
    Tidsskr Nor Laegeforen; 1996 Nov; 116(27):3226-30. PubMed ID: 9011975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH).
    Denti L; Pasolini G; Cortellini P; Sanfelici L; Benedetti R; Cecchetti A; Ferretti S; Banchini A; Ablondi F; Valenti G
    J Endocrinol Invest; 1999; 22(10 Suppl):70-1. PubMed ID: 10727053
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2002; (1):19-22. PubMed ID: 11877966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA
    Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment for benign prostatic hyperplasia. Several trials have shown benefit of finasteride.
    Collins GN
    BMJ; 1997 Aug; 315(7104):371. PubMed ID: 9270474
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug treatment for benign prostatic hyperplasia. Health authorities must audit use of finasteride.
    Mendelsohn R; Thompson D
    BMJ; 1997 Aug; 315(7104):370-1. PubMed ID: 9270473
    [No Abstract]   [Full Text] [Related]  

  • 11. Benign prostatic hyperplasia (BPH).
    Harv Mens Health Watch; 2006 Aug; 11(1):3. PubMed ID: 17111474
    [No Abstract]   [Full Text] [Related]  

  • 12. Finasteride therapy for benign prostatic hyperplasia.
    Helling TJ
    CMAJ; 2008 Feb; 178(5):596-7. PubMed ID: 18299551
    [No Abstract]   [Full Text] [Related]  

  • 13. [Finasteride in prolonged therapy of patients with benign prostatic hyperplasia].
    Mazo EB
    Urologiia; 2001; (3):20-2. PubMed ID: 11505535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
    Atan A
    J Urol; 1998 Jul; 160(1):134. PubMed ID: 9628630
    [No Abstract]   [Full Text] [Related]  

  • 15. Finasteride for BPH.
    Johnson KH; Casey CM
    J Fam Pract; 1998 Jun; 46(6):455-6. PubMed ID: 9638104
    [No Abstract]   [Full Text] [Related]  

  • 16. 5alpha-reductase inhibitors/finasteride.
    Stoner E
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia.
    Hochberg DA; Basillote JB; Armenakas NA; Vasovic L; Shevchuk M; Pareek G; Fracchia JA
    J Urol; 2002 Apr; 167(4):1731-3. PubMed ID: 11912398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finasteride to prevent morbidity from benign prostatic hyperplasia.
    Wasson JH
    N Engl J Med; 1998 Feb; 338(9):612-3. PubMed ID: 9475770
    [No Abstract]   [Full Text] [Related]  

  • 20. Current management and future trends in benign prostatic hyperplasia (BPH).
    Fitzpatrick JM
    Ir Med J; 1997 Nov; 90(7):256, 258. PubMed ID: 10036815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.